← Leaderboards
Kathrin M Bernt
Boston Children'S Hospital
$6,275,207
Attributed
$6,275,207
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,275,207 · 6
By mechanism
R01$4,734,459 · 3
U54$1,880,868 · 2
K08$659,880 · 1
Top collaborators
- Liming Pei2 shared
- Kai Tan2 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Meena Nathan$674,866
- Juan M Melero-Martin$14,050,839
- Gil Alterovitz$3,979,654
Others in their field
Top investigators on “Chromatin”
- Michael P Snyder · Yale University$98,050,605
- Bing Ren · Ludwig Institute For Cancer Research$76,818,585
- John A Stamatoyannopoulos · Regulome Corporation$56,022,526
- Bradley E Bernstein · Brigham And Women'S Hospital$44,846,223
- Eric J Nestler · Icahn School Of Medicine At Mount Sinai$42,440,927
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$40,714,772
Research focus
ChromatinMediatingLoss Of FunctionMalignant NeoplasmsLeukemiaGenetic TranscriptionCellsMemberEpigenetic ProcessBone Marrow CellsProgramsHematopoieticProgenitorInsightHematopoietic Stem CellsGenesOverexpressionMutationIn VivoNovel TherapeuticsCessation Of LifeLeukemogenesisAcute Myelocytic LeukemiaIn Vitro
Grant awards (24)
A stalled chromatin regulatory network that mediates the oncogenic activity of Meningioma-1$438,480
R01 · FY2025 · CA · contact PI
IDP mediated transcriptional stabilization as a cause of AML$236,433
R01 · FY2025 · CA · contact PI
A stalled chromatin regulatory network that mediates the oncogenic activity of Meningioma-1$416,556
R01 · FY2024 · CA · contact PI
IDP mediated transcriptional stabilization as a cause of AML$37,818
R01 · FY2024 · CA · contact PI
A stalled chromatin regulatory network that mediates the oncogenic activity of Meningioma-1$429,710
R01 · FY2023 · CA · contact PI
IDP mediated transcriptional stabilization as a cause of AML$381,343
R01 · FY2023 · CA · contact PI
A stalled chromatin regulatory network that mediates the oncogenic activity of Meningioma-1$350,480
R01 · FY2022 · CA · contact PI
IDP mediated transcriptional stabilization as a cause of AML$289,950
R01 · FY2022 · CA · contact PI
Center for Developmental Mapping of Heart and Bone Tissues$500,000
U54 · FY2021 · HL
Organ Specific Project - Bone Marrow$440,434
U54 · FY2021 · HL · contact PI
Center for Developmental Mapping of Heart and Bone Tissues$500,000
U54 · FY2020 · HL
Organ Specific Project - Bone Marrow$440,434
U54 · FY2020 · HL · contact PI
The role of H3K79 methylation in IDH-mutant leukemia$436,506
R01 · FY2020 · CA · contact PI
The role of H3K79 methylation in IDH-mutant leukemia$423,410
R01 · FY2019 · CA · contact PI
The role of H3K79 methylation in IDH-mutant leukemia$438,616
R01 · FY2018 · CA · contact PI
The role of H3K79 methylation in IDH-mutant leukemia$428,638
R01 · FY2017 · CA · contact PI
The role of H3K79 methylation in IDH-mutant leukemia$10,000
R01 · FY2017 · CA · contact PI
The role of H3K79 methylation in IDH-mutant leukemia$416,519
R01 · FY2016 · CA · contact PI
H3K79 Methylation in Hematopoietic Stem Cell Development and MLL-Rearranged Leuk$131,490
K08 · FY2014 · HL · contact PI
H3K79 Methylation in Hematopoietic Stem Cell Development and MLL-Rearranged Leuk$131,490
K08 · FY2013 · HL · contact PI
H3K79 Methylation in Hematopoietic Stem Cell Development and MLL-Rearranged Leuk$110,000
K08 · FY2012 · HL · contact PI
H3K79 Methylation in Hematopoietic Stem Cell Development and MLL-Rearranged Leuk$22,300
K08 · FY2012 · HL · contact PI
H3K79 Methylation in Hematopoietic Stem Cell Development and MLL-Rearranged Leuk$132,300
K08 · FY2011 · HL · contact PI
H3K79 Methylation in Hematopoietic Stem Cell Development and MLL-Rearranged Leuk$132,300
K08 · FY2010 · HL · contact PI